In a recent episode of the PharmaSource podcast, Arul Ramadurai, Chief Commercial Officer at Axplora, discusses the company’s strategic focus on high-growth therapeutic areas and its customer-driven investment philosophy.
Strategic Focus on High-Growth Therapeutic Areas
Axplora has positioned itself in two of the fastest-growing therapeutic areas: GLP-1 peptides and antibody-drug conjugates (ADCs). The company recently announced a €50 million investment in itsMourenx site in Southwest France for GLP-1 manufacturing capabilities. This investment enhances the site’s position as a center of excellence for contract manufacturing of APIs and drug substances for FDA-approved biologics.
In the ADC space, Axplora’s dominance is clear. They currently supply 40% of the world’s marketed ADCs and 50% of FDA-approved ADCs, making them a global leader. The company recently announced a new cutting-edge payload manufacturing workshop at their Le Mans site to further strengthen this position.
Customer-Driven Investment Philosophy
Axplora’s expansion strategy is distinctly customer-led rather than speculative. The company works closely with customers in North America, Europe, and Asia to develop solutions for capacity needs in the coming years. This approach has led to multiple strategic investments across Europe, including expansions at the Mourenx site, a new workshop for ADCs in Le Mans, and ongoing investments in Leverkusen, Germany.
Technical Expertise as a Competitive Advantage
Axplora’s technical edge in both GLP-1 and ADC manufacturing stems from its heritage. The company’s history in chromatography, particularly from the Novasep business, positions it as a leader in purification processes. This expertise is critical in manufacturing complex molecules like GLP-1s and ADCs, which require advanced purification and industrial chemistry capabilities.
To listen to the full podcast episode, visit: Axplora Strategy Teardown: Investing in High-Growth Therapeutics with a Customer-Driven Approach
Latest news
News
July 09, 2026
Axplora’s European CDMO network raises the bar with enhanced EcoVadis ratings across four manufacturing sites
Axplora’s Leverkusen site was awarded Platinum, with Le Mans receiving Gold, and Pompey and Chasse-sur-Rhône Silver in their first individual EcoVadis assessments. Recognition reinforces Axplora’s commitment to helping customers navigate increasingly complex supply chains with confidence through responsible, transparent and reliable manufacturing. 9 July, 2026 – Axplora, a global CDMO Partner for complex […]
News
June 10, 2026
Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen focus on Steroids and HPAPI leadership June 10th, 2026 – Axplora, a global leader in the manufacturing of small molecule APIs and ADCs for the pharmaceutical industry, today announced the strategic consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the PharmaZell business unit. Production will transition fully from the […]
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.